Twins have long played a role in the world of medical research, specifically in the area of clinical trials, where they can help measure the effectiveness of a therapy by applying a control to one of a genetically-similar pair.
Today, a startup founded by a former principal scientist at Pfizer, which has developed a way of digitising this concept through the use of AI, is announcing some funding to further its efforts. Unlearn.AI, which has built a machine learning platform that builds “digital twin” profiles of patients that become the controls in clinical trials — is announcing that it has raised $12 million in a Series A round.
The round is being led by 8VC with previous investors DCVC, DCVC Bio and Mubadala Capital Ventures also participating.
The startup’s DiGenesis platform is first being applied to neurological diseases, specifically Alzheimer’s Disease and Multiple Sclerosis, where effective treatment options remain an elusive goal and it has been hard to build clinical trials around patients with already-impacted health.
Read More at TechCrunch
Read the rest at TechCrunch